Everyone at Leadiant Biosciences works with rare dedication to provide therapies for patients with rare diseases. We partner with patient communities, physicians and researchers worldwide to overcome challenges and be a resource of hope.


Leadiant Biosciences, formerly known as Sigma-Tau Rare Disease, is a research-based global pharmaceutical company that dedicates considerable resources to the development, registration and commercialization of novel and effective therapies that address patient needs and improve quality of life.

Founded in Italy in 1957, we take pride in seeing value in compounds that others miss and strive to bring novel therapies to market that transform the lives of the patients we serve.

Our experienced, passionate team combines proven therapies and a commitment to delivering treatments to patients who need them. As a private company, we focus first and foremost on serving patients while also prioritizing a meaningful return to our shareholders. We continually reinvest in our company and technology to enhance our ability to develop the next generation of pharmaceuticals used to meet the challenges of specific diseases.

Leadiant Biosciences S.p.A. operates as a holding for all the business operative Leadiant entities as well as Exelead Inc., also providing legal, financial and administrative services to the Group. The company will define the targets and strategic directions of the Group, as well as the strategic guidelines and economic-financial drivers.

Leadiant Biosciences operates as Leadiant Biosciences, Inc. in the United States and Canada and Leadiant Biosciences, Ltd. in Europe.